Impact of peritransplant alemtuzumab levels on the risk of mixed chimerism. (A) Cumulative incidence curves of the incidence of mixed chimerism stratified by alemtuzumab levels of ≤0.15, 0.16 to 4.35, and ≥4.36 μg/mL. (B) Cumulative incidence curves of the incidence of mixed chimerism stratified by alemtuzumab levels of ≤0.15 vs ≥0.16 μg/mL. (C) Cumulative incidence curves of the incidence of mixed chimerism stratified by multiple alemtuzumab levels.